Baker Avenue Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.5M | Buy |
59,347
+53,452
| +907% | +$7.04M | 0.14% | 121 |
|
|
2026
Q1 | $822K | Buy |
5,895
+4,067
| +222% | +$570K | 0.02% | 307 |
|
|
2025
Q4 | $224K | Sell |
1,828
-1,272
| -41% | -$155K | 0.01% | 584 |
|
|
2025
Q3 | $344K | Buy |
3,100
+245
| +9% | +$27.8K | 0.01% | 442 |
|
|
2025
Q2 | $317K | Buy |
2,855
+365
| +15% | +$38.8K | 0.01% | 374 |
|
|
2025
Q1 | $279K | Buy |
+2,490
| New | +$257K | 0.01% | 370 |
|
|
2023
Q4 | – | Sell |
-598
| Closed | -$44.8K | – | 800 |
|
|
2023
Q3 | $44.8K | Sell |
598
-145
| -20% | -$11.2K | ﹤0.01% | 535 |
|
|
2023
Q2 | $57.3K | Buy |
743
+141
| +23% | +$11.2K | ﹤0.01% | 510 |
|
|
2023
Q1 | $49.9K | Buy |
602
+320
| +113% | +$26.5K | ﹤0.01% | 531 |
|
|
2022
Q4 | $24.2K | Buy |
+282
| New | +$22.3K | ﹤0.01% | 586 |
|
|
2022
Q2 | – | Sell |
-4,800
| Closed | -$285K | – | 313 |
|
|
2022
Q1 | $285K | Buy |
4,800
+901
| +23% | +$57.6K | 0.01% | 271 |
|
|
2021
Q4 | $283K | Buy |
3,899
+399
| +11% | +$27.5K | 0.01% | 272 |
|
|
2021
Q3 | $244K | Buy |
+3,500
| New | +$246K | 0.01% | 234 |
|
|
2017
Q4 | – | Sell |
-2,590
| Closed | -$210K | – | 236 |
|
|
2017
Q3 | $210K | Sell |
2,590
-250
| -9% | -$19.1K | 0.02% | 214 |
|
|
2017
Q2 | $201K | Buy |
+2,840
| New | +$189K | 0.03% | 193 |
|
|
2017
Q1 | – | Sell |
-2,910
| Closed | -$208K | – | 209 |
|
|
2016
Q4 | $208K | Sell |
2,910
-1,131
| -28% | -$84.1K | 0.03% | 195 |
|
|
2016
Q3 | $320K | Sell |
4,041
-22,184
| -85% | -$1.8M | 0.05% | 166 |
|
|
2016
Q2 | $2.19M | Sell |
26,225
-3,289
| -11% | -$292K | 0.33% | 76 |
|
|
2016
Q1 | $2.71M | Buy |
29,514
+311
| +1% | +$28K | 0.41% | 59 |
|
|
2015
Q4 | $2.96M | Buy |
29,203
+4,318
| +17% | +$449K | 0.42% | 64 |
|
|
2015
Q3 | $2.44M | Sell |
24,885
-9,118
| -27% | -$1.01M | 0.43% | 59 |
|
|
2015
Q2 | $3.98M | Buy |
34,003
+8,320
| +32% | +$909K | 0.53% | 53 |
|
|
2015
Q1 | $2.52M | Buy |
25,683
+920
| +4% | +$93.4K | 0.33% | 91 |
|
|
2014
Q4 | $2.33M | Buy |
24,763
+2,564
| +12% | +$265K | 0.32% | 91 |
|
|
2014
Q3 | $2.36M | Sell |
22,199
-9,915
| -31% | -$971K | 0.33% | 95 |
|
|
2014
Q2 | $2.66M | Sell |
32,114
-3,940
| -11% | -$307K | 0.38% | 90 |
|
|
2014
Q1 | $1.9M | Buy |
36,054
+15,774
| +78% | +$1.24M | 0.32% | 95 |
|
|
2013
Q4 | $1.52M | Buy |
+20,280
| New | +$1.41M | 0.29% | 85 |
|
Other funds holding GILD
Baker Avenue Asset Management's GILD Position: Q2 2026 in Review
Baker Avenue Asset Management increased its Gilead Sciences (GILD) stake by 907% in Q2 2026, buying an estimated $7.04M and bringing the position to 59,347 shares worth $7.5M. The position accounts for 0.14% of the portfolio, ranked #121.
Baker Avenue Asset Management first reported a position in GILD in Q4 2013 and has held it in 28 quarters since. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Baker Avenue Asset Management held 59,347 shares of Gilead Sciences worth $7.5M as of Q2 2026.
- Baker Avenue Asset Management bought 53,452 Gilead Sciences shares in Q2 2026, an estimated $7.04M.
- Gilead Sciences made up 0.14% of Baker Avenue Asset Management's portfolio in Q2 2026, its #121 holding.
- Baker Avenue Asset Management first reported a position in Gilead Sciences in Q4 2013 and has held it in 28 quarters since.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Baker Avenue Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.